Odyssey Therapeutics Partners with Evotec on AI-Driven Autoimmune Drug Discovery
ODTX sits 46% above its 52-week low of $15.1.
Summary
Odyssey Therapeutics has entered a strategic R&D collaboration with Evotec to discover small molecule treatments for autoimmune and inflammatory diseases. The deal combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform and compound libraries. Evotec will receive milestone payments for delivering validated hit series, though financial terms were not disclosed. This partnership adds a new discovery-stage pipeline leg to Odyssey's recently IPO'd platform, following positive Phase 2a data for lead candidate OD-001 in June. The collaboration could accelerate early-stage research and broaden Odyssey's pipeline in high-value indications.
At the time of this announcement, ODTX was trading at $21.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $15.10 to $21.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: EQS.